Cancer Institute and Hospital, Chinese Academy of Medical Sciences clinical trial pipeline

4 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 3 with minor changes only.

1. Notable

   Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition…Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma

   Enrollment reopened

   Also in this update: Primary completion pushed from Jul 1, 2026 to Dec 1, 2026

   Cancer Institute and Hospital, Chinese Academy of Medical Sciences·Phase 2· NCT06342167· Registry history of NCT06342167 on ClinicalTrials.gov (opens the registry)

   Oct 7, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.